| |
|
|
Session 61
Poster Presentations Treatment Initiated during Primary HIV Infection Thursday 1:30 - 3:30 pm Hall A |
| 512 | Structured Treatment Interruptions in Acute HIV Seroconverters: Preliminary Results of the Multicenter Prospective PRIMSTOP Pilot Trial (ANRS 100) B. Hoen*1, C. Lacabaratz2, I. Fournier3, I. Charreau3, M. Burgard4, F. Raffi5, P. Morlat6, T. May7, J. P. Aboulker3, A. Venet2, C. Rouzioux4, Primstop Study Group 1Univ Med Ctr of Besançon, France; 2Fac Med, Le Kremlin-Bicêtre, France; 3SC10 INSERM, Villejuif, France; 4Hosp Necker, Paris, France; 5Univ Med Ctr of Nantes, France; 6Univ Med Ctr of Bordeaux, France; and 7Univ Med Ctr of Nancy, France |
| 513 | Predictors of Plasma HIV RNA Control after Discontinuation of HAART Initiated at Acute Infection A. Lafeuillade*1, E. Counillon2, C. Poggi1, G. Hittinger1, D. Emilie3 1Gen Hosp, Toulon, France; 2Gen Hosp, Frejus, France; and 3INSERM, Clamart France |
| 514 | The Early Effect of Highly Active Antiretroviral Therapy During Acute Retroviral Syndrome is Associated with the Time of Starting and the Duration of Symptoms P. Vanhems*1, N. Voirin2, JP. Routy3, D. Baratin4, M. Legault3, C. Trépo5, P. Miaihles5, M. R. Boulassel3, J. M. Livrozet4, J. L. Touraine4, J. Fabry1, study collaborators6 1Edouard Herriot Hosp and INSERM U271, Lyon, France; 2INSERM U271, Lyon, France; 3McGill Univ Hlth Ctr, Montreal, Canada; 4Edouard Herriot Hosp, Lyon, France; 5Hôtel Dieu Hosp and INSERM U271, Lyon, France; and 6Montreal and Lyon Ctrs, Canada |
| 515 | T-cell Subset Perturbations During the First Interruption Phase of Subjects Treated During Primary HIV Infection: Activation and CCR5 Expression Correlate with Viral Load J. Zaunders*1, M. Munier2, P. Cunningham1, D. Smith2, P. Grey2, D. Quan3, R. McFarlane4, A. Kelleher2, D. A. Cooper2 1St Vincent's Hosp, Sydney, Australia; 2Natl Ctr In HIV Epidemiology Clin Res, Sydney, Australia; 3Holdsworth House Gen Practice, Sydney, Australia; and 4407 Doctors, Sydney, Australia |
| 516 | Analysis of Treatment-associated Viral Load Change During Primary HIV Infection P. Grey1, M. Johnston2, K. Petoumenos1, T. Ramacciotti1, P. Cunningham3, E. Rosenberg2, D. Smith*1, G. Robbins2, R. Finlayson4, D. Cooper1, B. Walker2, J. Kaldor1, C. Corcoran2, A. Carr3 1Univ of New South Wales, Sydney, Australia; 2Massachusetts Gen Hosp and Harvard Med Sch, Boston; 3St Vincent's Hosp, Sydney, Australia; and 4Taylor Square Private Clin, Sydney, Australia |
| 517 | Impact of Therapeutic Interruptions in Patients Treated during Primary Infection C. Goujard*1, C. Deveau2, M. Sinet3, C. Jacomet4, C. Lascoux5, T. Allegre6, H. Bazin7, C. Rouzioux8, J. F. Delfraissy1, L. Meyer2 1Bicêtre Hosp, Le Kremlin-Bicêtre, France; 2INSERM U569, Bicetre Hosp, Le Kremlin-Bicetre, France; 3INSERM E0109, Le Kremlin-Bicetre, France; 4Clermont-Ferrand, France; 5St Louis Hosp, Paris, France; 6Aix en Provence, France; 7Caen, France; and 8Necker Hosp, Paris, France |
| 518 | CD4 Activation Predicts Virologic Failure in HAART for Primary HIV F. M. Hecht*1, R. Gascon1, L. Liu1, S. Deeks1, J. Kahn1, M. Chesney1, R. Grant1, M. Busch2, M. McGrath1 1Univ of California at San Francisco and 2Blood Ctrs of the Pacific |
| 519 | Is HAART for Primary/Early HIV Infection Associated with Improved Outcomes After Treatment Discontinuation? F. M. Hecht*1, L. Wang2, A. Collier3, J. Margolick4, S. Little5, M. Kilby6, C. Benson7, B. Conway8, E. Daar9, M. Markowitz10, S. Holte2 1Univ of California at San Francisco; 2Fred Hutchinson Cancer Res Ctr, Seattle, WA; 3Univ of Washington, Seattle; 4Johns Hopkins, Baltimore, MD; 5Univ of California at San Diego; 6Univ of Alabama, Birmingham; 7Univ of Colorado, Denver; 8Univ of British Columbia, Vancouver, Canada; 9Univ of California at Los Angeles; and 10Aaron Diamond AIDS Res Ctr, New York, NY |
| 520 | The QUEST Cohort: Treatment of Primary HIV Infection with Quadruple HAART: Week 48 Preliminary Results S. Kinloch*1, D. Cooper2, F. Lampe1, D. Smith2, G. Janossy1, B. Hoen3, A. Sonnerborg4, C. Tsoukas5, A. Phillips1, L. Goh6, L. Perrin7 1Royal Free Hosp and Univ Coll, London, UK; 2St Vincent’s Hosp Med Ctr, Sydney, Australia; 3Univ de Franche-Comte, Besancon, France; 4Huddinge Univ Hosp, Stockholm, Sweden; 5Montreal Gen Hosp, Canada; 6GlaxoSmithKline, Greenford, UK; and 7Hosp Cantonal, Geneva, Switzerland |
| 521 | Viral Blips During HAART in Primary HIV Infection M. Di Mascio*1, M. Markowitz2, M. Louie2, C. Hogan2, V. Simon2, A. Hurley2, D. D. Ho2, A. S. Perelson1 1Los Alamos Natl Lab, NM and 2Aaron Diamond AIDS Res Ctr, New York, NY |